Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran versus placebo in adults with heterozygous familial hypercholesterolemia and elevated LDL-C
NL-OMON48935Phase 3Active, not recruiting
- Sponsor
- The Medicines Company
- Start
- Jan 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hypercholesterolemia (FH) comparing Inclisiran with Placebo (2 arms). Primary endpoints: Percentage change in LDL-C from baseline to Day 510 and Time-adjusted percentage change in LDL-C from baseline after Day 90 up to Day 540. Started Jan 2018; status: active, not recruiting.
02
Drugs
inclisiran
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON48935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48935.